Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 8/20 | 0.49 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | PTPN5 | P54829 | 4/20 | 0.43 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.43 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.43 |
| ▸ | NAAA | Q02083 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | KMO | O15229 | 1/20 | 0.40 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.39 |
| ▸ | PTGDR | Q13258 | 3/20 | 0.39 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.39 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.37 |
| ▸ | UGT1A9 | O60656 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.37 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.37 |
| ▸ | TTR | P02766 | 1/20 | 0.37 |
| ▸ | ALB | P02768 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4969723 | 1.00 | PTGDR2 (0.49) | PTGDR2AKR1B1PTPN5DUSP3PTPN11 | |
| SCHEMBL1998542 | 0.98 | PTGDR2 (0.47) | PTGDR2AKR1B1PTPN5DUSP3PTPN11 | |
| SCHEMBL2550680 | 0.85 | PTGDR2 (0.56) | PTGDR2AKR1B1NAAATHRBTDP1 | |
| SCHEMBL5226189 | 0.84 | KDM4E (0.40) | PTGDR2PTPN5NAAAPTPN2KDM4E | |
| Hydrochloric Acid SCHEMBL11528572 | 0.84 | PTGDR2 (0.55) | PTGDR2AKR1B1NAAATHRBTDP1 | |
| SCHEMBL3633503 | 0.83 | PTGDR2 (0.54) | PTGDR2AKR1B1NAAATDP1PTGDR | |
| SCHEMBL2916746 | 0.82 | GABRA1 (0.53) | PTGDR2PTPN5NAAAPTPN2PTGS2 | |
| SCHEMBL10772495 | 0.82 | GABRA1 (0.53) | PTGDR2PTPN5NAAAPTPN2PTGS2 | |
| SCHEMBL11392647 | 0.82 | PTGDR2 (0.43) | PTGDR2THRBKMOPTGDRPTGER2 | |
| SCHEMBL4058553 | 0.82 | PTGDR2 (0.41) | PTGDR2PTPN5NAAAKMOPTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090285891-A1 | Pharmaceutical preparation for oral administration with controlled active ingredient release in the small intestine and method for its production | DR. R. PFLEGER CHEMISCHE FABRIK GMBH (DE) | 2009-11-19 | — | — | US | claimed |
| EP-1968980-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES, LTD. (IN) | 2008-09-17 | — | — | EP | claimed |
| EP-1888525-A1 | 3,6-DISUBSTITUTED AZABICYCLO [3.1.0]HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2008-02-20 | — | — | EP | claimed |
| WO-2007110782-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2007-10-04 | — | — | WO | claimed |
| WO-2006117754-A1 | 3,6-DISUBSTITUTED AZABICYCLO [3.1.0] HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-11-09 | — | — | WO | claimed |
| US-10857517-B2 | Porous chiral materials and uses thereof | NANKAI UNIVERSITY (CN) | 2020-12-08 | — | — | US | disclosed |
| US-20120294938-A1 | PHARMACEUTICAL PREPARATION FOR ORAL ADMINISTRATION WITH CONTROLLED ACTIVE INGREDIENT RELEASE IN THE SMALL INTESTINE AND METHOD FOR ITS PRODUCTION | Dr. R. Pflefger Chemische Fabrik GmbH (DE) | 2012-11-22 | — | — | US | disclosed |
| US-8221787-B2 | Pharmaceutical preparation for oral administration with controlled active ingredient release in the small intestine and method for its production | Dr. Robert Pfleger Chemische Fabrik GmbH (DE) | 2012-07-17 | — | — | US | disclosed |
| US-20090285891-A1 | Pharmaceutical preparation for oral administration with controlled active ingredient release in the small intestine and method for its production | DR. R. PFLEGER CHEMISCHE FABRIK GMBH (DE) | 2009-11-19 | — | — | US | disclosed |
| WO-2009060203-A1 | 3,4,6,7-TETRAHYDRO-1 H-PYRROLO[3,4-D]PYRIMIDINE-2,5-DIONES AND THEIR THERAPEUTIC USE | ARGENTA DISCOVERY LIMITED (GB) | 2009-05-14 | — | — | WO | disclosed |
| US-20080319043-A1 | 3,6-Disubstituted Azabicyclo (3.1.0) Hexane Derivatives as Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2008-12-25 | — | — | US | disclosed |
| US-7446123-B2 | Azabicyclo derivatives as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2008-11-04 | — | — | US | disclosed |
| EP-1888525-A1 | 3,6-DISUBSTITUTED AZABICYCLO [3.1.0]HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2008-02-20 | — | — | EP | disclosed |
| US-20060287380-A1 | Azabicyclo Derivatives as Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2006-12-21 | — | — | US | disclosed |
| WO-2006117754-A1 | 3,6-DISUBSTITUTED AZABICYCLO [3.1.0] HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-11-09 | — | — | WO | disclosed |
| EP-1620087-A1 | AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES, LTD. (IN) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004089364-A1 | AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319043-A1 | 3,6-Disubstituted Azabicyclo (3.1.0) Hexane Derivatives as Muscarinic Receptor Antagonists | CHRM3, CHRM5, CHRM2 | PTGDR2 229/4885AKR1B1 513/4885PTPN5 1241/4885 |
| US-10857517-B2 | Porous chiral materials and uses thereof | ANXA7, XDH, OPRM1 | PTGDR2 4033/4885AKR1B1 3111/4885PTPN5 1155/4885 |
| US-20060287380-A1 | Azabicyclo Derivatives as Muscarinic Receptor Antagonists | CHRM3, CHRM2, CHRM5 | PTGDR2 150/4885AKR1B1 342/4885PTPN5 1009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.